Le Lézard
Classified in: Health
Subject: PER

nThrive Welcomes New Leaders to Growing Organization


ALPHARETTA, Ga., Feb. 22, 2018 /PRNewswire/ -- nThrive, an independent Patient-to-PaymentSM solutions company, is pleased to announce the newest additions to its leadership. Bringing these members on to the team is another important step nThrive is taking toward delivering its vision to empower health care for every one in every community.

Joining the executive leadership team are Bernard Gay, Chief Information Officer and Rhonda Vetere, President, Data and Analytics. In addition, Ellen Zane, a seasoned health care executive and industry subject matter expert will be joining the nThrive Board of Directors. After a thoughtful process, the company has selected these accomplished individuals representing a full spectrum of in-depth experience that will be of great value to the continued growth of nThrive.

Bernard Gay, as Chief Information Officer (CIO), leads the Technology Services organization. With more than 16 years of experience in managing Information Technology (IT) organizations at a senior executive level, including serving as global vice president and chief technology officer at Royal Caribbean Ltd., senior vice president and chief information officer of Atlantis and most recently serving as chief information officer of Delaware North, Gay has demonstrated the ability to transform IT Organizations into high performing teams that add value across all segments of the business. At Delaware North, he led a team of IT professionals and directed the business and technical vision for the company. Bernard has a proven track record of organizational transformation, systems and operational management, and client service. He will lead by developing a long-term cloud strategy, managing the nThrive data centers, and optimizing the IT infrastructure to serve as an industry competitive differentiator.

Rhonda Vetere, as President, Data and Analytics, brings her leadership and breadth of experience to add to the company's continued focus and investment in health care data and analytics. She joins nThrive as it launches a major initiative to embed analytics into nThrive technology solutions and capitalize on its market potential.

Vetere is an accomplished and industry recognized global executive, specializing in transformation of worldwide information technology operations, ranging from product development and support to strategic development and implementation of technology infrastructure. Formerly, she served as chief technology officer for Estee Lauder Companies, responsible for global infrastructure, applications, service delivery, operations, security, analytics, architecture and strategy for IT. During her tenure, Vetere transformed the company's technology, digital, social and retail technology approach.

Rhonda has received numerous accolades for her leadership. Most recently, she won a 2017 Stevie® Award for Excellence in Transforming Business, competing with more than 1,500 CIOs and CTOs, for the prestigious honor. In addition she was awarded Top 100 global Executives in STEM [Science Technology Engineering and Math].

Ellen Zane joins the nThrive Board of Directors. Zane brings with her a wealth of industry knowledge from an accomplished career. She is the former president and chief executive officer of the internationally respected 450-bed Tufts Medical Center and the Floating Hospital for Children in Boston. Zane was the first woman to hold this position in the institution's 200+ year history. She continues to serve on as vice-chair of the Board of Trustees of Tufts Medical Center and holds two faculty appointments at Tufts University School of Medicine, as well as serving as adjunct assistant professor of Health Policy and Management at the Harvard T.H. Chan School of Public Health. Zane has made her mark in health care throughout her career, including tenure as a Network President for Partners HealthCare System, a 5,000+ provider network with over $800 million of managed care revenue, and as chief executive officer at Quincy Hospital in Quincy, Massachusetts. She is a sought after health care expert who serves on a number of boards and has received multiple honors for her work in health care, as a leader among women in business, and for her philanthropic associations.

About nThrive
From Patient-to-PaymentSM, nThrive provides all the technology, advisory expertise, services, analytics and education programs health care organizations need to thrive in the communities they serve. Formerly known as MedAssets, Precyse and Equation, nThrive is built on a legacy of excellence. Most recently, nThrive acquired two leaders in their fields, Adreima ? a provider of patient-centered, clinically integrated revenue cycle services that help patients find coverage and meet their financial obligations ? and e4e Healthcare Services ? a business process outsourcing company. The five organizations together combine top talent and capabilities in the health care industry into a single enterprise. www.nthrive.com

Media Contact:
Francesca Richards, nThrive
484-948-1553 
[email protected]

SOURCE nThrive


These press releases may also interest you

at 08:07
On the evening of May 5, Kexing Biopharm (stock code: 688136) announced it had obtained a "Certificate of GMP Compliance of a Manufacturer" granted by the Norwegian Medical Products Agency in accordance with the European Medicines Agency (EMA)...

at 08:05
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET. The presentation will...

at 08:05
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 10,...

at 08:05
Viridian Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming...

at 08:05
$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results in the wind down of the PUR1900 Phase 2b study and allows for a significant...

at 08:01
Intensity Therapeutics, Inc. ("Intensity" or "the Company") , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase...



News published on and distributed by: